Apalutamide

證據等級: L5

預測適應症: 10 個

Apalutamide: From Prostate Cancer to Male Reproductive Organ Cancer

One-Sentence Summary

Apalutamide (Erleada®) is a second-generation androgen receptor (AR) inhibitor approved in the US and EU for metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC), though not yet marketed in Taiwan. The TxGNN model predicts it may be effective for Male Reproductive Organ Cancer broadly — a category spanning multiple prostate cancer stages and subtypes — with 50+ clinical trials and 18 publications supporting this direction. Evidence is anchored by the landmark Phase 3 TITAN and SPARTAN trials, placing this prediction at the highest evidence level (L1).

Quick Overview

Item	Content
Original Indication	Prostate cancer (mCSPC; nmCRPC)
Predicted New Indication	Male Reproductive Organ Cancer
TxGNN Prediction Score	97.41%
Evidence Level	L1
Taiwan Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Note on prediction selection: TxGNN’s highest-ranked prediction (Rank 1: “prostate cancer/brain cancer susceptibility”, score 98.43%) represents a genetic susceptibility category rather than a treatment target — the repurposing rationale in the evidence pack explicitly flags this as a likely knowledge-graph proximity artifact with no direct mechanistic link. This report therefore focuses on Male Reproductive Organ Cancer (Rank 8, score 97.41%) as the most evidence-supported and clinically actionable prediction.

Why is This Prediction Reasonable?

Apalutamide is a potent, selective second-generation nonsteroidal androgen receptor inhibitor. It binds directly to the ligand-binding domain of the AR, blocking AR nuclear translocation and DNA binding, thereby preventing transcriptional activation of androgen-responsive genes that drive tumor cell proliferation and survival. Unlike first-generation antiandrogens such as bicalutamide, apalutamide remains fully antagonistic even under conditions of AR overexpression — a key feature underlying its superior clinical efficacy.

Prostate cancer is the dominant malignancy within the “male reproductive organ cancer” disease category, and it is fundamentally an AR-dependent disease across all stages: hormone-sensitive (castration-naïve), castration-resistant, non-metastatic, and metastatic. Because Apalutamide’s mechanism directly targets the core growth driver of prostate cancer, the TxGNN prediction captures a well-grounded mechanistic and biological overlap. The TxGNN score reflects the high node-proximity between Apalutamide’s pharmacological targets and the disease nodes within the knowledge graph — not simply a spurious correlation.

Beyond already-approved indications, Phase 3 trials are actively evaluating Apalutamide in additional clinical settings within this disease category: neoadjuvant and adjuvant therapy for high-risk localized prostate cancer (NCT03767244, n=2,517), adjuvant post-prostatectomy therapy (NCT04295447), and combination with radiotherapy for locally advanced disease (NCT04557059). The prediction therefore aligns closely with Apalutamide’s established and emerging clinical development trajectory, identifying a label-broadening opportunity that extends well-characterised AR-inhibition benefits across the full spectrum of male reproductive organ cancers.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03767244	Phase 3	Active, Not Recruiting	2,517	Apalutamide + ADT vs placebo + ADT before and after radical prostatectomy in high-risk localized/locally advanced prostate cancer; co-primary endpoints: pathological complete response rate and metastasis-free survival
NCT02489318	Phase 3	Active, Not Recruiting	1,052	TITAN: Apalutamide + ADT vs ADT alone in metastatic hormone-sensitive prostate cancer; demonstrated superior radiographic progression-free survival and overall survival
NCT04557059	Phase 3	Active, Not Recruiting	694	Apalutamide added to radiotherapy + LHRHa in high-risk hormone-sensitive prostate cancer; progressive disease defined by PSMA-PET imaging
NCT06592924	Phase 3	Recruiting	830	Addition of docetaxel to androgen receptor pathway inhibitor therapy in mCSPC patients with suboptimal PSA response
NCT03124433	Phase 2	Completed	30	NEAR trial: Neoadjuvant apalutamide monotherapy before radical prostatectomy in D’Amico intermediate-to-high-risk prostate cancer; evaluated tumor downstaging and oncologic efficacy
NCT01171898	Phase 1/2	Completed	127	First-in-human study of ARN-509 in advanced castration-resistant prostate cancer; established the tolerable dose range, pharmacokinetics, and proof-of-concept activity
NCT02903368	Phase 2	Completed	118	Neoadjuvant + adjuvant abiraterone + apalutamide for intermediate-to-high-risk prostate cancer undergoing prostatectomy; assessed pathological response and tissue/radiographic biomarkers
NCT03899077	Phase 2	Unknown	202	Salvage radiotherapy + 6-month ADT vs salvage radiotherapy + apalutamide in hormone-naïve patients with biochemical progression after radical prostatectomy
NCT04295447	Phase 2	Active, Not Recruiting	190	Adjuvant apalutamide vs standard of care in high-risk prostate cancer post-prostatectomy; primary endpoint: biochemical recurrence-free survival
NCT02867020	Phase 2	Completed	128	Head-to-head comparison of abiraterone + ADT vs apalutamide monotherapy vs abiraterone + apalutamide in hormone-naïve locally advanced or metastatic prostate cancer

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33914595	2021	Phase 3 RCT	J Clin Oncol	TITAN final survival analysis: Apalutamide + ADT significantly improved OS and rPFS in mCSPC after unblinding and placebo-to-apalutamide crossover
29420164	2018	Phase 3 RCT	N Engl J Med	SPARTAN: Apalutamide significantly extended metastasis-free survival vs placebo in high-risk non-metastatic CRPC
31150574	2019	Phase 3 RCT	N Engl J Med	TITAN first analysis: Apalutamide + ADT prolonged radiographic PFS and overall survival in metastatic castration-sensitive prostate cancer
32907777	2021	Phase 3 RCT Follow-up	Eur Urol	SPARTAN final OS analysis: Apalutamide confirmed overall survival benefit in nmCRPC with PSA doubling time ≤10 months
38261983	2024	Phase 3 RCT	J Clin Oncol	PRESTO: Intensification of androgen blockade with apalutamide + abiraterone in high-risk biochemically relapsed castration-sensitive prostate cancer after radical prostatectomy
36167599	2023	Phase 2 RCT	Eur Urol	ARNEO: Neoadjuvant degarelix with or without apalutamide before radical prostatectomy in high-risk prostate cancer; evaluated androgen deprivation response
35091711	2022	Phase 2 Trial	Prostate Cancer Prostatic Dis	NEAR trial: Neoadjuvant apalutamide monotherapy with radical prostatectomy in intermediate-to-high-risk prostate cancer; efficacy and tumor downstaging outcomes
39417629	2025	Comparative Study	The Prostate	Real-world multicenter comparison of abiraterone, enzalutamide, and apalutamide in mHSPC; assessed differential efficacy and safety across ARPI agents
33480983	2021	Review	Endocr Rev	Comprehensive review of hormonal therapy evolution in prostate cancer from gonadal testosterone deprivation to direct AR inhibition; covers resistance mechanisms
32930958	2020	Drug Review	Drugs	Apalutamide (Erleada®) clinical pharmacology review in mCSPC; summarises Phase 3 TITAN data, dosing, tolerability, and regulatory status

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — Second-generation nonsteroidal androgen receptor (AR) inhibitor
Myelosuppression Risk	Low — not a conventional cytotoxic agent; clinically significant myelosuppression is not an expected adverse effect
Emetogenicity Classification	Low
Monitoring Items	Thyroid function (TSH; hypothyroidism risk), liver function (ALT/AST), PSA (treatment response), bone density (fracture risk with prolonged androgen deprivation), neurological assessment (falls/seizure risk)
Handling Protection	Standard handling; dedicated cytotoxic drug handling protocols not required

Safety Considerations

Please refer to the SmPC for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple Phase 3 RCTs — including TITAN (mCSPC, n=1,052) and SPARTAN (nmCRPC) — have firmly established Apalutamide’s efficacy and safety across the prostate cancer spectrum, constituting L1-level evidence for the male reproductive organ cancer category. The drug’s AR-inhibition mechanism is well-characterised and directly aligned with disease biology. However, Apalutamide is currently not marketed in Taiwan, and complete local safety data are not yet available for this evidence pack.

To proceed, the following is needed:

Taiwan TFDA market authorisation application and regulatory pathway analysis
Full SmPC safety review, with particular attention to drug-drug interactions (Apalutamide is a strong CYP3A4 and CYP2C19 inducer with clinically significant interaction potential)
Taiwan-specific pharmacoeconomic analysis and National Health Insurance reimbursement strategy
Definition of priority patient population for initial Taiwan market entry (nmCRPC vs mCSPC vs neoadjuvant/adjuvant settings)
Long-term safety monitoring plan addressing fractures, falls, cardiovascular events, and hypothyroidism
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.